Skip to main content
Best News Website or Mobile Service
WAN-IFRA Digital Media Awards Worldwide
Best News Website or Mobile Service
Digital Media Awards Worldwide
Hamburger Menu




US CDC tells states to prep for COVID-19 vaccine distribution as soon as late October

US CDC tells states to prep for COVID-19 vaccine distribution as soon as late October

FILE PHOTO: A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia Sep 30, 2014. (REUTERS/Tami Chappell/File Photo)

WASHINGTON: The US Centers for Disease Control and Prevention (CDC) has asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October, documents published by the agency showed on Wednesday (Sep 2).

The timing of a vaccine has taken on political importance as US President Donald Trump seeks re-election in November, after committing billions of federal dollars to develop a vaccine to prevent COVID-19, which has killed more than 180,000 Americans.

"For the purpose of initial planning, CDC provided states with certain planning assumptions as they work on state specific plans for vaccine distribution, including possibly having limited quantities of vaccines in October and November," a CDC spokeswoman told Reuters.

READ: US FDA to bring independent experts to review COVID-19 vaccines

The New York Times had earlier reported that the CDC had contacted officials in all 50 states and five large cities with the planning information.

The country's top infectious disease expert Anthony Fauci earlier on Wednesday said on MSNBC that based on the patient enrollment rate in COVID-19 vaccine trials underway, there could be enough clinical data to know by November or December that one of the vaccines is safe and effective.

The documents put online by the New York Times showed the CDC is preparing for one or two vaccines for COVID-19 to be available in limited quantities as soon as late October.

The vaccines would be made available free of cost first to high-risk groups including healthcare workers, national security personnel, and nursing home residents and staff, the agency said in the documents.

Regulators around the world have repeatedly said development speed will not compromise vaccine safety, as quicker results would stem from conducting parallel trials that are usually done in sequence. But such reassurances have not convinced everyone.

READ: Emergency authorisation of COVID-19 vaccines needs great care: WHO

READ: 5 things you need to know about a COVID-19 vaccine

Preliminary results of a survey conducted over the last three months in 19 countries showed that only about 70 per cent of British and US respondents would take a COVID-19 vaccine if available, Scott Ratzan, co-leader of a group called Business Partners to Convince, told Reuters in August.

Drug developers including Moderna, AstraZeneca and Pfizer are leading the race to develop a safe and effective vaccine for the respiratory illness.

The CDC documents describe two vaccine candidates that must be stored at temperatures of -70 degrees Celsius and -20 degrees Celsius. Those storage requirements match profiles of candidates from Pfizer and Moderna.

READ: Poor countries desperate for COVID-19 vaccines may be outbid by richer neighbours

Last month, the US health department said the CDC was executing an existing contract option with McKesson Corp to support potential vaccine distribution.

CDC Director Robert Redfield has asked state governors to expedite McKesson's requests for building vaccine distribution centres and to consider waiving requirements that would stop them from becoming fully operational by Nov 1, according to a recent letter obtained by Reuters. 

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: Reuters/kv


Also worth reading